Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735694 | 0.98 | LAP3 (0.52) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL11333556 | 0.93 | CYP3A4 (0.44) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL15772432 | 0.91 | S1PR2 (0.46) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL29232553 | 0.85 | CYP3A4 (0.53) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL10421805 | 0.85 | CYP3A4 (0.53) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL3644479 | 0.85 | LAP3 (0.48) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28814 | 0.83 | SMPD1 (0.63) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL6580829 | 0.82 | S1PR2 (0.49) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8377533 | 0.82 | SMPD1 (0.67) | LAP3S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL2745581 | 0.82 | SMPD1 (0.67) | LAP3S1PR2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2932 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| US-9328347-B2 | siRNA useful in the treatment of flavivirus infection | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-05-03 | — | — | US | claimed |
| US-8846631-B2 | MicroRNA compositions and methods | Regulus Therapeutics Inc. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140287023-A1 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES | UNIV MCGILL (CA) | 2014-09-25 | — | — | US | claimed |
| US-20140248336-A1 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-09-04 | — | — | US | claimed |
| WO-2014124433-A1 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-08-14 | — | — | WO | claimed |
| WO-2013012835-A2 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-01-24 | — | — | WO | claimed |
| JP-2003525017-A | — | — | 2003-08-26 | — | — | JP | claimed |
| JP-2002526072-A | — | — | 2002-08-20 | — | — | JP | claimed |
| JP-2002520051-A | — | — | 2002-07-09 | — | — | JP | claimed |
| EP-1115859-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| EP-1098969-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1071753-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-01-31 | — | — | EP | claimed |
| WO-2000017346-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| WO-2000004141-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1999054459-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-28 | — | — | WO | claimed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | claimed |